Indication intelligence, analysis and sector perception

Lower open expected; RegMed sector speculation is as high as it ever was …

February 23, 2016 6:41am

… Important is the price-volume action of stem, cell and gene therapy regenerative medicine stocks

Confidance has not enhanced conviction.

Why, subscribe … http://www.regmedinvestors.com/create-account

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …

Dow futures are DOWN -0.1% and NASDAQ futures are DOWN -0.3%

U.S. stock futures pointed to a dip at the open Tuesday, with the Dow industrials poised to give back part of Monday’s 229-point gain.

European equities were trading largely flat after a global rally faded overnight.

Asia stocks lost momentum with major indexes slipping as an overnight improvement in market sentiment ran out of steam

Data docket: a December reading for the Case-Shiller home price index is due at 9 a.m. ET. A January figure for existing home sales and February data on consumer confidence are both slated to come at 10 a.m. Federal Reserve Vice Chairman Stanley Fischer is expected to deliver a speech on monetary policy in Houston at 8:30 p.m. ET.

The stem, cell and gene therapy RegMed sector closed POSITIVE on Monday and Friday, NEGATIVE on Thursday, POSITIVE on Wednesday and last Tuesday.

Past five (5) days (of 43 covered companies):

· Monday closed POSITIVE with 8 decliners, 32 advancers and 3 flats

· Friday closed POSITIVE with 17 decliners, 23 advancers and 3 flat;

· Thursday closed NEGATIVE with 19 decliners, 11 advancers and 3 flat;

· Wednesday closed POSITIVE with 3 decliners, 37 advancers and 3 flats;

· Last, Tuesday closed POSITIVE with 6 decliners, 36 advancers and 1 flat;

The stem, cell and gene therapy regenerative medicine (SCGT&RM) Monday’s session traded mostly in narrow ranges <except in a few number of cases> as the sector closed higher Monday.

I don't think this environment has changed in the last week. I think it’s a lot of short covering!

The NASDAQ’s technicals have also improved markedly over the past week – four (4) positive closes out of five (5) days. A test of lows was followed by two (2) impressive up days which sets up usually for depreciation.

Volume, however, was not convincing on these two up days!

There are not a lot of “bottoms” being formed by SCGT&RM sector companies however, sector “participants are improving subtly.

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you - what copuld be Tuesday’s trades?

Applied Genetic Technologies (AGTC) closed UP +$0.45 to $15.20. Starting with 2/9/16’s $12.06, AGTC has had a good run but, has it peaked as traders “nibble” the edges of appreciation – SELL;

Intrexon (XON) closed UP +$0.26 to $32.68. 2/29/16, XON will admit financial results, will we be seeing a dip pre Q4/15 results. The after-market indication is -$0.32 - SELL;

Athersys (ATHX) closed UP +$0.18 to $1.78. ATHX was down Friday -$0.09 and has an aftermarket indication of +$0.10 – BUY;

Capricor (CAPR) closed FLAT to $2.43 on moderate volume <18.5 K as average volume = 23.4 K shares>. Remember 1/19/16’s $2.03, what’s keeping it up as NO news has been attributed to this equity after a failed offering that will re-start as soon as another banker can “flog” the “hedgies” – SELL;

Juno Therapeutics (JUNO) closed DOWN -$1.91 to $33.71 after Friday’s -0.15. JUNO will report Q4/15 results on 2/29/16. The after-market indication is -$0.21 – BUY to SELL;

Kite Pharma (KITE) closed DOWN - $1.51 to $46.62 on volume of 895.7 K shares <average 3 month = 1.19 M shares>. The after-market indication is -$0.47 – SELL;

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.